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Sarcoidosis and spondyloarthritis: A coincidence or 
common etiopathogenesis? 
 
 
Abstract 
Background: Sarcoidosis is a multisystem granulomatous disease. Co-existence with 
spondyloarthritis (SA) has been more described as an adverse effect of anti-TNF α therapy 
than an association. We report herein a case of a typical sarcoidosis confirmed by 
histological proofs and an advanced SA with a bamboo column. 
Case Presentation: A 48-years-old woman presented with inflammatory back pain for 5 
years and ankle swelling for 1 year. On physical examination, she had an exaggerated 
dorsal kyphosis and disappearance of lumbar lordosis with limitation in motion of the 
cervical and lumbar spine. Laboratory tests did not show an inflammatory syndrome or 
hypercalcemia. Plain radiographies of the spine and pelvic revealed a triple ray appearance 
with sacroiliitis grade 4. Chest radiography and CT confirmed the presence of bilateral 
hilar lymph nodes and parenchymal nodes. Bronchoscopy and biopsies were performed 
showing non-calcified granulomatous reaction without cell necrosis. The diagnosis of SA 
was performed based on 9 points of Amor criteria associated with pulmonary sarcoidosis. 
She was treated with 15 mg per week of methotrexate and 1mg/kg/day of prednisone for 
pulmonary disease with good outcomes. 
Conclusions: Sarcoidosis may be associated to SA besides paradoxical drug effect. The 
same physio pathological pathways mediate by TNF α are arguments for association than 
hazardous coincidence. 
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Sarcoidosis is a multisystem disease characterized by the occurrence of a non-
calcified granulomatous reaction. The exact pathogenesis of this disease is still unknown, 
but it seems that it is caused by an inappropriate cellular immune response against 
environmental or infectious agents (1). This disease may present with different clinical 
features. It can mimic several rheumatic diseases or can develop concomitantly to them. 
The sacroiliac joint involvement is less frequent and can be found in 6.6% cases among 
patients with authentic sarcoidosis (2). Sacroiliitis is the hallmark of spondyloarthritis 
(SA). SA encompasses several chronic rheumatic disorders that share clinical features and 
a genetic association with human leukocyte antigen B27 (HLA-B27) (3). Common 
symptoms of SA-related diseases include inflammatory back pain, peripheral arthritis, 
enthesitis, and extra-articular features, such as psoriasis, inflammatory bowel disease, and 
uveitis. Most cases of co-existing sarcoidosis and SA published are described as an 
adverse effect of anti-tumor necrosis factor alpha (TNF α) therapy (4). Since both diseases 
share a same pathophysiological background based on the role of TNF α, co-existence 
seems to be an association rather than a hazardous event. We report herein a new case of 
pulmonary sarcoidosis discovered simultaneously associated to an axial evolved SA naïve 
of anti-TNF α therapy.  
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Case Presentation 
A 48 years-old woman was admitted in January 2015 to 
the Rheumatology Department of the National Institute of 
Orthopedics of Tunisia with complaints of inflammatory low 
back pain and a morning stiffness of one hour for 5 years. 
The history of the patient has revealed a recent swelling and 
heel pain and red eyes two times last year. She declared no 
shortness of breath or other breathing troubles. Furthermore, 
the patient’s personal and family past medical history was 
unremarkable. On physical examination, she had typical SA 
appearance with exaggerated dorsal kyphosis and 
disappearance of lumbar lordosis. A significant limitation in 
motion of the cervical and lumbar spine was noted and the 
Faber’s test and Patrick’s test were positive. Peripheral joint 
examination revealed swelling of ankles. Tenderness was 
noted in the insertion of Achilles tendon and plantar fascia. 
Systemic evaluation was normal except the crackle sounds in 
the lower zones of lungs. A routine laboratory assessment 
was unremarkable with a normal rate of serum calcium, 
sedimentation rate and C-reactive protein. Tuberculin skin 
test was negative. X-ray examination revealed typical 
finding of SA with a bilateral sacroiliitis grade 4 (figure 1), a 
triple ray in the lumbar and cervical spine. A pelvic CT 
confirmed the sacroiliitis fusion (figure 2). 
 
 
 
 
 
 
 
 
 
Figure 1: Pelvic x-rays showed a bilateral sacroiiitis grade 4 
 
 
 
 
 
 
 
 
 
 
Figure 2: Frontal view of the sacroiliac joints showing 
sarcoiliitis grade 4 of Forestier 
Chest X-ray showed a mediastinal enlargement and a 
reticulonodular infiltrate in the middle and lower lungs 
(figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Chest x-rays showed mediastinal enlargement 
and a reticulonodular infiltrate in the middle and lower 
lungs 
 
The chest CT scan confirmed the presence of several and 
bilateral hilar lymph nodes and parenchymal nodes. The 
pulmonary functional tests showed a restrictive syndrome. 
Since sarcoidosis was suspected, bronchoscopy and biopsies 
were performed showing non-calcified granulomatous 
reaction without cell necrosis. Ophthalmologist examination 
showed bilateral sequela of anterior uveitis.  
The patient cumulated 9 points of Amor criteria 
confirming the diagnosis of SA. A co-occurrence of axial 
and peripheral SA and sarcoidosis was established. The 
patient was treated with 15 mg per week of methotrexate and 
1mg/kg/day of prednisone for pulmonary disease with good 
outcomes. 
 
 
Discussion 
Up to this date, the co-occurrence of sarcoidosis and SA 
was reported in 17 cases. The originality of our case was the 
discovery in mean time of a typical SA with ankylosed 
sacroiliac joints and bamboo column  and typical hilar lymph 
nodes of sarcoidosis. 
In previous cases reported, female outnumbered male 
(sex ratio: 4.1), with age range varying from 42 to 70 years-
old. Sarcoidosis was the first disease diagnosed in 7 cases. 
Simultaneous diagnosis of both diseases was done in 8 
patients as in our case.  Ankle involvement was the most 
reported articular manifestation.  One case of advanced SA 
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with a bamboo column as in our patient was reported (5). As 
a complication of both diseases, anterior uveitis was 
diagnosed in one case (6). 
Sacroiliitis has been rarely described in sarcoidosis, 
mainly in case reports.Different diagnosis may be discussed: 
pyogenic or mycobacterial infection, malignant process or 
sarcoid infiltration. While the prevalence of SA in general 
population is 1 to 1.9%, sacroiliac joint involvement was 
found in 6.6% of 61 sarcoid patients in one study (7) and in 
14.3% of 42 sarcoid patients in another study (8). In both 
studies, the diagnosis of SA was retained for all patients with 
sacroiliitis based on ASAS or ESSG criteria. Only one 
patient of the first study was positive for HLA-B27. Also by 
reviewing the 17 cases of coexisting sarcoidosis and SA, 
HLA-B27 was positive only in 4 patients. Rareness of 
association with common HLA marker of SA suggests that 
different genetic factors may be involved in the coexistence 
of the two diseases. HLA-DR5 has been found in sarcoid 
patients. Different genetic bases (HLA class 1 in SA and 
HLA class 2 in sarcoidosis) suggest that the association was 
a coincidence rather than common etiopathogenesis. 
Nevertheless both diseases have some common features like 
uveitis, interstitial lung disease, sacroiliitis and good 
response to anti-TNF α therapy.  
In fact, immunomodulatory agents like anti-TNF α have 
proven their efficiency in sarcoidosis treatment (9). The three 
drugs evaluated were infliximab in 232 cases, etanercept in 
26 cases and adalimumab in 8 cases (10). There was no 
study with golimumab or certolizumab. The three commonly 
used anti-TNF drugs were not equivalent. Infliximab has 
demonstrated improvement in multiorgan involvement of 
sarcoidosis: lung, eyes, brain, heart, skin and liver (11). 
Adalimumab has proven also its efficiency in sarcoidosis 
treatment even in the case of infliximab intolerance (12). 
However, etanercept has been studied only for lung 
involvement and has not demonstrated real improvement 
(13). 
Physiopathogenesis of efficiency of anti-TNF therapy has 
been explained by a humoral immune reaction. After an 
exogenous stimulus, immune response is initiated by 
activation of CD4+ T helper cells. The result is secretion of 
cytokines acting as chemoattractants and recruiting 
macrophages, neutrophils and other lymphocytes. Activation 
of these cells releases TNF α which activate in turn different 
signaling pathways and mediate granuloma formation (14). 
Thus, inhibition of TNF α should result in less granuloma 
formation. Monoclonal antibodies (infliximab and 
adalimumab) will bind quickly with strong affinity and low 
dissociation constant to soluble and membrane TNF α. On 
the other hand, soluble receptor (etanercept) binds only to 
soluble TNF α. This immune complex is less stable and will 
be rapidly eliminated in few minutes (15). In some particular 
situation and for unknown reasons, neutralization of 
peripheral TNF α is responsible of the activation of specific 
and auto-reactive lymphocyte T and the result is a granuloma 
formation and a sarcoid-like reaction (16).  
In 10 years time 71 cases of sarcoid induced reaction to 
anti-TNF therapy have been reported (17). Mainly the 
occurrence of respiratory signs despite a stable disease 
conducts physicians to perform chest x-ray or CT-scan. Hilar 
and mediastinal adenopathy were the most frequent 
pulmonary findings and the diagnosis of sarcoidosis was 
confirmed histologically in 90% of cases (18). Withdrawing 
the TNF treatment was associated to regression of the 
sarcoid-like reaction and in most cases steroids were used.    
In conclusions we describe a case of co-occurrence of 
sarcoidosis and evolved SA. The higher rate of sarcoidosis 
described as a paradoxical effect of anti-TNF α therapy than 
a coexistence with SA and physiopathological pathways 
mediate by TNF α are great arguments for coincidence of 
this association. 
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